The Solution

 

ELGAN Pharma is developing a therapy that is aimed to prevent the multifactorial visual deterioration of preterm infants.

 

The therapy is provided locally as eye drops,  it is a combination of compounds that target the complex aspects of the disease. The therapy is based on enhanced drug penetration profile using nano-particulate based formulation. The novelty is in the combination and route of administration, alongside the tailored formulation, these substantiate the company IP coverage.